

(FINAL/APPROVED)

VIRGINIA BOARD OF PHARMACY

PUBLIC HEARING FOR SCHEDULING CERTAIN CHEMICALS

November 28, 2018
Second Floor
Board Room 2

Perimeter Center
9960 Mayland Drive
Henrico, Virginia 23233-1463

CALL TO ORDER: The public hearing was called to order at 11:08a.m.

PRESIDING: Rafael Saenz, Chairman

MEMBERS PRESENT: James L. Jenkins, Jr.
Ryan K. Logan
Cheryl H. Nelson
Kristopher S. Ratliff
Patricia Richards-Spruill

MEMBERS ABSENT: Rebecca Thornbury
Cynthia Warriner
Glenn L. Bolyard, Jr.
Melvin L. Boone, Sr.

STAFF PRESENT: Caroline D. Juran, Executive Director
J. Samuel Johnson, Jr., Deputy Executive Director
Beth O'Halloran, Deputy Executive Director
Ellen B. Shinaberry, Deputy Executive Director
Elaine Yeatts, Senior Policy Analyst, DHP
James Rutkowski, Assistant Attorney General

PUBLIC HEARING FOR SCHEDULING OF CERTAIN CHEMICALS

PUBLIC COMMENT: Mr. Saenz called for comment to consider placement of Epidiolex into Schedule V.

The proposed changes to the Drug Control Act to conform with recent changes enacted by the DEA will be considered during the full board meeting, following the public hearing.


There was no public comment on the subject received at the meeting, however, two emails containing comment on this subject were reviewed by the board:

- Regina Whitsett, Executive Director of Substance Abuse Free Environment, Inc. (SAFE), provided support for the scheduling of the drug Epidiolex, an FDA-approved medication to treat intractable epilepsy, in Schedule V of the Virginia Drug Control Act to conform to DEA action.

- Mary Crozier, EdD and Chair of the Community Coalitions of Virginia (CCoVA), provided written comment in support of the scheduling of Epidiolex, an FDA-approved medication to treat intractable epilepsy, into Schedule V to conform to DEA action.


ADJOURN:

The public hearing adjourned at 11:09am.



Rafael Saenz, Chairman
12/18/18

Date



Caroline D. Juran, Executive Director
12/18/18

Date